8-K: Aeluma Reports Record FY25 Revenue, Strategic Contract Wins

Aeluma, Inc. announced strong financial results for fiscal year 2025, driven by record revenue and significant R&D contract acquisitions, positioning for continued growth.

Summary

• Aeluma, Inc. reported record revenue of $4.7 million for the full fiscal year ended June 30, 2025, a substantial increase from $919 thousand in the prior year.
• The company achieved a GAAP net loss of $3.0 million, or ($0.23) per basic and diluted share, for FY2025, an improvement from a $4.6 million net loss in FY2024.
• Adjusted EBITDA for FY2025 turned positive at $186 thousand, compared to a loss of $3.5 million in the prior year.
• For the fourth quarter of 2025, revenue was $1.3 million, with a GAAP net loss of $859 thousand, or ($0.05) per share, and an Adjusted EBITDA loss of $113 thousand.
• Aeluma closed FY2025 with a strong cash position of $15.7 million and no debt.
• The company secured six R&D contracts in fiscal year 2025, including two in the fourth quarter, with notable wins from NASA, the U.S. Navy, and the Department of Energy.
• Aeluma provided fiscal year 2026 revenue guidance in the range of $4.0 million to $6.0 million, focusing on new contract wins, team expansion, enhanced manufacturing readiness, and go-to-market traction.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to record revenue growth, a significant improvement in Adjusted EBITDA to positive territory, a strong cash position, and numerous strategic contract wins with key government agencies. The company's clear strategic priorities and positive outlook for FY2026 further bolster confidence, despite ongoing GAAP net losses which are common for companies in early commercialization phases.

Positives

• Full fiscal year 2025 revenue reached a record $4.7 million, a significant increase from $919 thousand in the prior year, demonstrating strong growth in R&D contracts.
• Adjusted EBITDA for FY2025 turned positive at $186 thousand, a substantial improvement from a $3.5 million loss in FY2024.
• GAAP net loss for FY2025 improved to $3.0 million from $4.6 million in the prior year.
• The company ended FY2025 with a robust cash and cash equivalents balance of $15.7 million, up from $1.3 million in FY2024, and remains debt-free.
• Secured six new R&D contracts in FY2025, including two in Q4, with key wins from NASA, the U.S. Navy (two contracts), and the Department of Energy, indicating strong market traction and validation of technology.
• Unveiled a manufacturing breakthrough in collaboration with Thorlabs, applicable to quantum computing and communication systems.
• Included in the broad-market Russell 3000 Index (effective June 30, 2025) and the MSCI Global Micro Cap Index (effective August 26, 2025), enhancing market visibility and liquidity.
• Appointed industry veteran Christopher Stewart as CFO, bringing over 20 years of financial leadership experience to support high-growth initiatives.

Negatives

• Reported a GAAP net loss of $859 thousand for the fourth quarter of 2025, and a full fiscal year GAAP net loss of $3.0 million.
• Adjusted EBITDA for the fourth quarter of 2025 was a loss of $113 thousand, although an improvement year-over-year.
• The decrease in GAAP net income from the prior quarter (Q3 2025) was primarily due to a $2.6 million non-cash gain in fair value of derivative liabilities recorded in Q3 2025, indicating that Q3's net income was not solely from operational performance.

Risks

• Actual results may differ materially from forward-looking statements due to known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the company's control, including those described in the company's other filings with the Securities and Exchange Commission.

Future Outlook

For the full fiscal year 2026, Aeluma expects revenue in a range of $4.0 million to $6.0 million. Strategic priorities include securing three to seven new development contracts, expanding the business development, technical, and operations teams, enhancing outsourced wafer manufacturing productivity and technology qualification, and increasing customer engagements in targeted commercial markets.

Management Comments

• Jonathan Klamkin, Ph.D., Founder and CEO, stated that throughout fiscal year 2025, the company continued to build momentum with increased manufacturing readiness, commercialization traction, and elevated market visibility following its Nasdaq uplist.
• Klamkin highlighted that Aeluma's transformative semiconductor technology uniquely positions the company to address critical needs in fast-growing market verticals such as AI infrastructure, defense and aerospace, mobile and consumer electronics, and quantum computing.
• Klamkin emphasized that the company's compelling customer value proposition is supported by a robust IP portfolio, domestic semiconductor capability, strategic R&D contracts, and a scalable, capital-light manufacturing model.
• Klamkin expressed belief that fiscal 2026 will be a year of significant progress in executing the go-to-market strategy and creating long-term value for shareholders, supported by a strong balance sheet and positive trends in target verticals.

Industry Context

Aeluma's focus on high-performance photonic and electronic technologies positions it within critical and rapidly expanding industry segments. Its semiconductor technology addresses needs in AI infrastructure, defense and aerospace, mobile and consumer electronics, and quantum computing, all of which are experiencing significant growth and demand for advanced, scalable solutions. The company's R&D contracts with entities like NASA, the U.S. Navy, and the Department of Energy underscore the strategic importance of its domestic semiconductor capabilities in national security and technological advancement.

Management Changes

Stakeholder Impact

• Shareholders: Potential for long-term value creation through strategic growth, increased market visibility from index inclusions (Russell 3000, MSCI Global Micro Cap), and improved financial performance (positive Adjusted EBITDA, reduced net loss).
• Employees: Expansion of the team, including business development, technical leadership, and operations, indicates job growth and opportunities.
• Customers: New R&D contracts and increased customer engagements in the pipeline suggest growing demand and successful product development, particularly in AI, defense, and quantum computing sectors.
• Partners: Collaboration with Thorlabs on manufacturing breakthroughs and expanded supply chain partnerships indicate strengthened relationships and potential for future joint ventures.
• Creditors: The company's strong cash position and no debt reduce credit risk.

Next Steps

• Host a conference call on September 9, 2025, to discuss financial results and business outlook.
• Pursue three to seven new development contracts in fiscal year 2026 to provide non-dilutive R&D funding and partnership opportunities.
• Expand the business development and go-to-market team, as well as technical leadership and operations staff.
• Enhance manufacturing readiness through higher outsourced wafer manufacturing productivity, expanded test and validation capabilities, technology qualification, and supply chain partnerships.
• Continue progress on opportunities in targeted commercial markets and increase customer engagements in the pipeline.

Key Dates

Recommendation

While Aeluma demonstrates strong revenue growth, significant improvement in Adjusted EBITDA, and strategic contract wins, it remains in an early commercialization phase with ongoing GAAP net losses. The positive momentum and future outlook are encouraging, but the company's ability to translate R&D contracts into sustained profitability and scale commercial operations warrants a 'hold' recommendation for now. Investors should monitor the execution of its go-to-market strategy and progress towards consistent profitability before a stronger 'buy' recommendation.

Keywords

Semiconductor, Photonic, AI Infrastructure, Defense, Aerospace, Quantum Computing, R&D Contracts, Financial Results, NASDAQ, Russell 3000, MSCI Global Micro Cap